The physiological levels of Asparagine recover faster after the administration of ASP Erwinia vs. preparations of ASP derived from E. coli2

Switching to Asparaginase Erwinia in patients with positive CA or allergy symptoms, reduced the risk of treatment failure rate from 3.2 to 0.62.

Patients with silent hypersensitivity, who continue to receive asparaginase derived from E. Coli, have worse results. This shows that the presence of AC anti-asparaginase (in the absence of allergy) and subsequent switch to Erwinia ASP could mitigate the adverse effects of silent hypersensitivity 2.

Due to the different bacterial source of ASP E. chrysanthemi, there is no cross-reactivity with antibodies generated against ASP derived from E. coli.

Patients who develop a hypersensitivity reaction and are switched to alternative ASP preparations produce similar clinical results to patients who did not have a hypersensitivity reaction.

The DFS in patients who received Erwinia asparaginase at 5.4 years was higher, compared to patients who never developed hypersensitivity reactions (86.5% and 81.3%).

The results showed that Asparaginase Erwinia Chrysanthemi was well tolerated and, more importantly, maintained asparaginase activity> 0.1 IU / ml at 48 and 72 h in all patients analyzed.

1. Burke. M., J. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia, Future Oncol. (2014) 10(16), 2615–2627. doi: 10.2217/fon.14.138. PMID: 24983955.

2. Cecconello. D., K., Magalhães. M., et al. Asparaginase: an old drug with new questions, hematol transfus cell ther. 2 0 2 0;4 2(3):275–282. doi.org/10.1016/j.htct.2019.07.010

3. Egler. R., A., Ahuja. S., P., et al. L‑asparaginase in the treatment of patients with acute lymphoblastic leukemia, J Pharmacol Pharmacother. 2016 Abr-Jun; 7(2): 62–71. doi: 10.4103 / 0976-500X.184769. PMID: 27440950; PMCID: PMC493608

4. Pieters, R.,Hunger. S.P., et al. L-asparaginase treatment in acute lymphoblastic leukemia: afocus on Erwinia asparaginase: Cancer. 2011 January 15; 117(2): 238–249. doi: 10.1002 /cncr.25489. Epub 2010 Sep 7. PMID: 20824725; PMCID: PMC3000881.

5. Plourde, P.V., et al. Safety Profile of Asparaginase Erwinia chrysanthemi in a Large Compassionate-Use Trial: Pediatr Blood Cancer 2014;61:1232–1238. doi: 10.1002 / pbc.24938. Epub 2014 Jan 16. PMID: 24436152.

6. Salzer, W., Bostrom. B., et al. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia, Leukemia & Lymphoma, 59:8, 1797-1806, doi: 10.1080 /10428194.2017.1386305. Epub 2017 Oct 18. PMID: 29045165.